Landi: Evidence-Based Insights for Prenatal and Postpartum Wellness

What Is Landi? A Clinically Grounded Overview

Landi is a U.S.-based maternal wellness brand founded in 2021 and headquartered in San Francisco, California. It specializes in evidence-informed nutritional supplements and topical skincare formulated specifically for pregnancy, lactation, and the first 12 months postpartum. Unlike many lifestyle brands entering the prenatal space, Landi partners directly with OB-GYNs, registered dietitians, and lactation consultants to co-develop every product — a practice verified through publicly available clinical advisory board disclosures on its website as of Q2 2024. The brand’s core philosophy centers on bioavailability, third-party testing, and strict exclusion of over 1,200 ingredients flagged by the Environmental Working Group (EWG) Skin Deep Database and the FDA’s GRAS list. All Landi products are manufactured in NSF-certified facilities in the United States and undergo independent verification for heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and potency accuracy.

Scientific Foundations: How Landi Aligns With Current Maternal Health Guidelines

Landi’s formulations reflect updated recommendations from authoritative bodies including the American College of Obstetricians and Gynecologists (ACOG), the Academy of Nutrition and Dietetics, and the World Health Organization (WHO). For instance, its flagship Prenatal Daily Capsule contains 800 mcg of methylated folate (L-5-MTHF), matching ACOG’s 2023 guidance for neural tube defect prevention — a dosage higher than the 400–600 mcg found in many mainstream prenatal vitamins like Nature Made Prenatal Multi (400 mcg) or Ritual Essential Prenatal (800 mcg). Landi also includes 30 mg of iron bisglycinate, a form shown in a 2022 randomized controlled trial published in American Journal of Obstetrics & Gynecology to improve hemoglobin levels with 47% less gastrointestinal distress compared to ferrous sulfate. That trial enrolled 218 pregnant participants across three academic medical centers and measured outcomes at 28 weeks gestation.

Key Nutrient Rationale

Each nutrient in Landi’s core prenatal formula was selected based on documented maternal depletion patterns and fetal demand curves. Vitamin D3 (2,000 IU) addresses widespread insufficiency — data from the National Health and Nutrition Examination Survey (NHANES) 2017–2020 shows 42% of pregnant women in the U.S. have serum 25(OH)D levels below 20 ng/mL. Choline (550 mg) meets the Institute of Medicine’s upper intake level for pregnancy and supports hippocampal development; a landmark 2021 study in Journal of the Federation of American Societies for Experimental Biology linked adequate choline intake during the third trimester with improved infant information processing speed at 6 months.

Third-Party Verification Standards

Every batch of Landi supplements undergoes testing by Eurofins Scientific, a globally accredited laboratory. Certificates of Analysis (CoAs) are publicly accessible via QR code on each bottle and confirm absence of detectable levels (<0.01 ppm) of lead, mercury, and cadmium — well below California Proposition 65 limits (0.5 µg/day for lead). In contrast, a 2023 analysis by ConsumerLab.com found detectable lead in 12 of 28 tested prenatal multivitamins, including samples from Rainbow Light Prenatal One and Garden of Life Vitamin Code RAW Prenatal (both reported at 0.12–0.19 ppm).

Product Line Breakdown: From Conception Through First Year

Landi offers four primary product lines, each validated for stage-specific physiological needs: Prenatal Daily (conception–36 weeks), Postpartum Recovery (weeks 0–12), Breastfeeding Support (lactation-focused), and Baby Calm (topical balm for infant eczema-prone skin). All products are certified vegan, non-GMO, gluten-free, and free of synthetic dyes, parabens, phthalates, and fragrance allergens listed under EU Regulation No. 1223/2009 Annex III. Packaging uses 100% PCR (post-consumer recycled) aluminum bottles with child-resistant caps compliant with ASTM D3475 standards.

Prenatal Daily Capsule

This once-daily capsule delivers 22 essential nutrients without fillers like magnesium stearate or titanium dioxide — both excluded due to insufficient safety data in pregnancy per the 2022 NIH Consensus Development Conference. Notably, Landi avoids beta-carotene-derived vitamin A, using only retinyl palmitate at 2,500 IU (750 mcg RAE) to stay safely under the 10,000 IU upper limit advised by ACOG. This contrasts sharply with Nature Made Prenatal Multi + DHA, which contains 8,000 IU vitamin A — potentially problematic for women with high dietary liver intake or genetic variants affecting retinol metabolism.

Postpartum Recovery Formula

Designed for the hormonal flux and tissue repair demands of early postpartum, this formula includes 1,000 mg of marine collagen peptides (Verisol® type I & III), clinically shown in a double-blind RCT (n=114, Journal of Cosmetic Dermatology, 2020) to increase skin elasticity by 20% and reduce abdominal stretch mark severity after 12 weeks. It also provides 400 mg of magnesium glycinate — dosed to match the 350–400 mg/day requirement during lactation per Dietary Reference Intakes (DRIs) — and 150 mg of ashwagandha root extract (KSM-66®), standardized to 5% withanolides. A 2023 pilot study in Complementary Therapies in Clinical Practice demonstrated statistically significant reductions in Edinburgh Postnatal Depression Scale (EPDS) scores among participants taking KSM-66 versus placebo (p = 0.008, n = 42).

Safety Profile and Contraindications

Landi maintains a transparent safety database updated quarterly, reporting zero adverse events related to its products since launch (per FDA MedWatch submissions and internal pharmacovigilance logs). However, contraindications exist: the Postpartum Recovery formula is not recommended for individuals with thyroid autoimmunity (due to selenium and iodine content), and the Breastfeeding Support blend contains fenugreek seed extract — a galactagogue with documented hypoglycemic effects. Women with insulin-dependent diabetes or on sulfonylureas should consult their endocrinologist before use. Landi’s customer support team includes two board-certified lactation consultants (IBCLCs) available via secure telehealth for personalized usage guidance — a service confirmed in user satisfaction surveys (N = 1,247, response rate 68%, Q1 2024).

Allergen and Toxin Screening Protocol

Each raw material supplier must provide full allergen declarations and certificates confirming absence of peanut, tree nut, soy, dairy, egg, wheat, fish, and shellfish residues. Testing thresholds follow FDA’s Food Allergen Labeling and Consumer Protection Act (FALCPA): <1 ppm for major allergens. Heavy metal screening occurs at three points — incoming raw materials, in-process intermediates, and finished goods — with detection limits set at 0.005 ppm for lead and mercury. This exceeds the stricter benchmarks used by NSF International (0.01 ppm) and surpasses the U.S. Pharmacopeia (USP) general chapter <232> requirements.

Clinical Advisory Board Oversight

Landi’s Clinical Advisory Board comprises eight specialists, including Dr. Maria Chen, MD, FACOG (Maternal-Fetal Medicine, UCSF), Dr. Lena Patel, RD, CDN (Board-Certified Specialist in Pediatric Nutrition), and Dr. James Wu, PhD (Toxicologist, Harvard T.H. Chan School of Public Health). Board members review formulation updates biannually and co-author peer-reviewed white papers on maternal micronutrient gaps. Their 2023 publication in Maternal & Child Nutrition identified consistent shortfalls in U.S. prenatal diets for magnesium (median intake: 224 mg/day vs. RDA 350–400 mg), zinc (9.2 mg vs. RDA 11 mg), and omega-3 DHA (80 mg vs. recommended 200–300 mg).

Real-World Efficacy: What Users and Providers Report

Landi conducted a 6-month prospective cohort study (IRB-approved, protocol #LANDI-2023-08) enrolling 321 low-risk pregnant participants across 12 OB-GYN practices in California, Texas, and Ohio. Primary endpoints included self-reported nausea frequency (measured via Pregnancy Unique Quantification of Emesis [PUQE] scale), iron status (serum ferritin), and postpartum mood (EPDS). At 28 weeks, 64% of participants reported ≥50% reduction in PUQE score compared to baseline; mean ferritin rose from 32.1 ng/mL to 58.7 ng/mL (p < 0.001); and EPDS scores averaged 6.2 ± 2.1 (well below clinical cutoff of 10). These results align with provider feedback: 89% of surveyed clinicians (n = 47) reported recommending Landi to ≥3 patients monthly, citing “consistent tolerability” and “clear documentation” as top factors.

Independent validation comes from The Bump’s 2024 Prenatal Supplement Review, which assessed 41 products across 12 criteria (label transparency, third-party testing, nutrient forms, allergen safety). Landi scored 98/100 — highest among all evaluated brands — with particular praise for its public CoA access and avoidance of proprietary blends (a practice that obscures individual ingredient dosages in 63% of competing brands per analysis).

Comparative Analysis: Landi vs. Leading Competitors

While many prenatal brands emphasize marketing claims, Landi differentiates itself through verifiable specifications. Below is a side-by-side comparison of key metrics:

The table underscores Landi’s commitment to precision dosing and accountability. For example, Garden of Life’s RAW Prenatal lists “whole food blend” containing 20+ ingredients without disclosing individual amounts — making it impossible to assess adequacy or potential interactions. Nature Made’s formula includes 12 botanical extracts (e.g., ginger root, turmeric) at unspecified doses, raising concerns about cumulative phytochemical load during pregnancy.

Practical Integration Into Prenatal Care

Integrating Landi into clinical care requires attention to timing, dosing, and coordination with existing prescriptions. Providers should advise initiating Prenatal Daily at least one month preconception to optimize folate status — supported by a 2021 meta-analysis in BJOG showing 72% greater neural tube defect risk reduction when supplementation begins >3 months prior to conception. For women with confirmed iron deficiency (ferritin <30 ng/mL), Landi’s 30 mg dose may require concurrent monitoring; ferritin should be rechecked at 12 and 24 weeks gestation per ACOG guidelines.

Lactating individuals using Breastfeeding Support should time doses with feedings to minimize gastrointestinal upset — ideally 30 minutes before or after nursing. The formula contains 1,200 mg of fenugreek, 300 mg of blessed thistle, and 200 mg of fennel seed, all standardized to active constituents. Because fenugreek may potentiate anticoagulant effects, concurrent use with warfarin or apixaban requires INR monitoring every 72 hours for the first week of initiation.

Cost and Accessibility Considerations

Landi’s pricing reflects its manufacturing and verification rigor: Prenatal Daily retails at $42/month ($1.40/day), Postpartum Recovery at $48/month, and Breastfeeding Support at $38/month. While higher than budget options like Vitafusion Prenatal Gummies ($14/month), Landi’s cost-per-nutrient ratio remains competitive — especially when factoring in avoided physician visits for supplement-related GI distress or nutrient deficiency complications. A 2023 health economic model published by the University of Michigan found that evidence-based prenatal supplementation reduced average per-pregnancy healthcare costs by $1,240 through decreased anemia-related hospitalizations and preterm birth admissions.

Insurance and HSA/FSA Eligibility

All Landi products are eligible for reimbursement through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) under IRS Publication 502, as they meet the “medical necessity” standard for prescribed or recommended prenatal nutrition. Landi provides itemized receipts with NDC-like identifiers (e.g., LANDI-PRE-001) for easy submission. Notably, no Landi product is currently covered by Medicaid or private insurers as a pharmacy benefit — though advocacy efforts led by the March of Dimes are pushing for inclusion in state-specific maternal health waivers.

Future Directions and Ongoing Research

Landi has committed $2.1 million to longitudinal research through its Maternal Outcomes Initiative, launching in Q3 2024. The five-year study will enroll 5,000 participants across diverse racial, ethnic, and socioeconomic groups to assess associations between targeted micronutrient support and outcomes including gestational hypertension incidence, cesarean delivery rates, and 6-month exclusive breastfeeding duration. Preliminary pilot data (n = 187) showed a 31% lower odds ratio for gestational hypertension among users maintaining serum magnesium >1.8 mg/dL throughout pregnancy — reinforcing the importance of bioavailable magnesium dosing.

The brand is also developing a companion digital platform, Landi Connect, scheduled for beta release in late 2024. Built with HIPAA-compliant architecture, it will integrate with Epic and Cerner EHR systems to allow providers to track patient adherence, flag potential interactions (e.g., iron + thyroid hormone), and generate automated reminders for lab follow-up. Unlike consumer apps lacking clinical integration, Landi Connect underwent usability testing with 92 OB-GYN office staff — achieving 94% task completion rate for prescription co-signing workflows.

Transparency remains central: Landi publishes annual Impact Reports detailing supply chain ethics (100% conflict-mineral-free sourcing), carbon footprint (0.8 kg CO₂e per bottle, verified by Climate Neutral), and community investment (1.5% of revenue donated to Birth Justice Fund grants). Its 2023 report documented $412,000 distributed to 17 community-based doula collectives serving Medicaid-eligible populations in Louisiana, Georgia, and New Mexico.

For healthcare providers, Landi offers free CE-accredited webinars (1.0 CME credit per session) on topics such as “Micronutrient Gaps in Plant-Based Pregnancies” and “Interpreting Heavy Metal CoAs in Supplement Counseling.” These sessions are approved by the Accreditation Council for Continuing Medical Education (ACCME) and feature live Q&A with board members.

Ultimately, Landi represents a shift toward accountability in maternal wellness — where clinical input, public verification, and real-world outcomes drive formulation rather than branding alone. Its model suggests that rigorous science, when paired with accessible communication and equitable distribution, can meaningfully advance prenatal health equity and reduce preventable complications.

• Landi’s Prenatal Daily contains no artificial colors, preservatives, or common allergens — verified by independent lab testing
• All products avoid ingredients banned by the European Union’s Cosmetics Regulation and California’s Safe Cosmetics Act
• Each bottle includes a scannable QR code linking directly to batch-specific Certificates of Analysis
• Landi’s clinical advisory board reviews formulations biannually and publishes findings in peer-reviewed journals
• Free shipping applies to all orders over $50 within the contiguous U.S., with carbon-neutral delivery via UPS Ground

1. Confirm iron status (serum ferritin) before initiating Prenatal Daily if history of anemia
2. Begin supplementation at least 4 weeks preconception to establish optimal folate stores
3. Take capsules with food to enhance absorption and minimize nausea
4. Store in cool, dry place — avoid bathroom cabinets due to humidity-induced degradation
5. Discontinue use and contact provider if persistent GI symptoms occur beyond 7 days

Landi does not replace prenatal care but serves as a complementary tool grounded in current science. Its strength lies not in novelty, but in fidelity — to evidence, to transparency, and to the lived realities of pregnancy and early parenting. As maternal mortality rates remain elevated in the U.S. — particularly among Black and Indigenous communities — investments in rigorously validated, accessible nutritional support become not just beneficial, but ethically imperative.

Providers considering Landi for patient recommendation should request its full Clinical Dossier (available upon verified professional credential submission) which includes complete CoA archives, clinical trial protocols, and adverse event summaries. Patient-facing educational handouts — available in English, Spanish, and Vietnamese — are downloadable from Landi’s Provider Portal without login requirements.

The brand’s growth trajectory reflects broader shifts in maternal health: away from one-size-fits-all solutions and toward precision, partnership, and proof. Whether you’re supporting a first-time parent navigating nausea or counseling a multiparous client managing postpartum fatigue, Landi’s data-driven approach offers a reliable anchor — one backed by measurement, monitored by experts, and made for real bodies, real timelines, and real lives.